Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Am J Geriatr Psychiatry. 2018 Nov 3;27(3):322–332. doi: 10.1016/j.jagp.2018.10.016

Figure 2.

Figure 2.

The proportion of patients (A) and study partners (B) responding they would be “extremely likely” to participate in trial vignettes of three different risk strata, dependent upon whether the trial did not (MCI trial) or did (Prodromal AD trial) enroll only individuals meeting amyloid PET biomarker inclusion criteria.